Calgary Tribune - Moderna announces positive results for Omicron vaccine

NYSE - LSE
RBGPF 0.24% 76.2 $
BCC -1.54% 66.37 $
CMSC -0.73% 19.14 $
GSK -0.08% 50.41 $
NGG -0.01% 84.28 $
RIO -3.62% 80.05 $
BTI 0.35% 62.11 $
AZN -0.23% 184.02 $
RELX -0.17% 40.44 $
BCE 3.16% 22.13 $
CMSD -0.33% 18.86 $
VOD -0.39% 15.31 $
JRI -1.8% 11.09 $
RYCEF -0.51% 17.71 $
BP -1.74% 44.92 $
Moderna announces positive results for Omicron vaccine
Moderna announces positive results for Omicron vaccine / Photo: Joseph Prezioso - AFP

Moderna announces positive results for Omicron vaccine

US biotech company Moderna on Wednesday announced positive results for a new vaccine that targets both the original Covid strain and Omicron.

Text size:

This so-called "bivalent" vaccine was tested in a trial of more 850 adults, who had all received their first three doses of Moderna's original Spikevax vaccine.

Around half the group then received a fourth dose of Spikevax, while the rest received the bivalent vaccine.

Those who received the bivalent vaccine had significantly higher levels of neutralizing antibodies -- Y-shaped immune system proteins that block the virus -- against Omicron.

On average, these levels were around 75 percent higher in the group who got the bivalent vaccine as a fourth dose compared to those who got the original vaccine as a fourth dose. They also received slightly superior protection to the ancestral strain of Covid compared to Spikevax.

"We are thrilled," said Stephane Bancel, CEO of Moderna in a statement, adding he anticipated this vaccine would be the company's lead candidate for authorization as a booster this fall.

"We want to be as ready as early as August for shipping," he told investors in a call.

Stephen Hoge, the company's president, did concede that antibody levels would be lower against Omicron's sub variants that are now in circulation, but said he believed it was still a superior booster than repeating Spikevax.

The company doesn't yet have data on durability -- how the new vaccine booster will fare three months and six months out.

A panel of Food and Drug Administration experts will meet June 28 to discuss considerations and strategies for boosters in fall and winter.

A.Nelson--CT